Peter Chase, MD
Professor, Pediatrics-BDC, Pediatrics-Endocrinology
Clinic Phone:
303-724-2323
Specialty:
Pediatric Endocrinology (Juvenile Diabetes)
Location:
Aurora - Barbara Davis Center for Childhood Diabetes - Specialty Clinic
Conditions & Treatments:
Child and Teen Health - Juvenile Diabetes
Gender: Male
Language:
English
Medical Schools
MD, University of Wisconsin School of Medicine and Public Health (1961)
MD, University of Wisconsin School of Medicine and Public Health (1961)
Undergraduate Schools
BS, University of Wisconsin System (WI) (1958)
BS, University of Wisconsin System (WI) (1958)
Residency Program
Stanford University Program, Pediatrics (1964)
Stanford University Program, Pediatrics (1964)
Fellowships
Stanford University Program, Pediatrics (1965)
National Institutes of Health Clinical Center Program, Pediatrics (1967)
Stanford University Program, Pediatrics (1965)
National Institutes of Health Clinical Center Program, Pediatrics (1967)
Specialty
Pediatrics - Pediatric Endocrinology (Juvenile Diabetes), Board Certification
Pediatrics - Pediatric Endocrinology (Juvenile Diabetes), Board Certification
Conditions & Treatments
Child and Teen Health - Juvenile Diabetes
Child and Teen Health - Juvenile Diabetes
Hospital Affiliation
Children's Hospital Colorado
Children's Hospital Colorado
Clinical Location
Barbara Davis Center for Childhood Diabetes - Specialty Clinic
1775 Aurora Ct.
Aurora, CO 80045
Website
303-724-2323 (Phone)
303-724-6779 (Fax)
Barbara Davis Center for Childhood Diabetes - Specialty Clinic
1775 Aurora Ct.
Aurora, CO 80045
Website
303-724-2323 (Phone)
303-724-6779 (Fax)
Job Titles
Academic - Professor
Academic - Professor
American Diabetes Association,
Outstanding Physician Clinician in Diabetes
(2001)
Juvenile Diabetes Research Foundation, Lifetime Achievement Award (2003)
Juvenile Diabetes Research Foundation, Lifetime Achievement Award (2003)
American Diabetes Association
American Pediatric Society (APS)
Society for Pediatric Research (SPR)
Federation of American Societies for Experimental Biology
The American Society for Clinical Nutrition
Western Society for Pediatric Research
American Pediatric Society (APS)
Society for Pediatric Research (SPR)
Federation of American Societies for Experimental Biology
The American Society for Clinical Nutrition
Western Society for Pediatric Research
Research Interests
Clinical trials of agents for the prevention of type I diabetes, including cyclosporine, nicotinamide, BCG and the subcutaneous and intravenous administration of insulin. He is currently one of nine center directors for the Diabetes Prevention Trial (DPT-1). Continuous glucose monitoring (CGM) in children has been a recent area of emphasis. The use of CGM to prevent severe hypoglycemia and to improve HbA1c levels is currently being studied
Clinical trials of agents for the prevention of type I diabetes, including cyclosporine, nicotinamide, BCG and the subcutaneous and intravenous administration of insulin. He is currently one of nine center directors for the Diabetes Prevention Trial (DPT-1). Continuous glucose monitoring (CGM) in children has been a recent area of emphasis. The use of CGM to prevent severe hypoglycemia and to improve HbA1c levels is currently being studied
Clinical Interests for Referring Providers: Pediatric Diabetes
Research Interest for Referring Providers: Clinical trials of agents for the prevention of type I diabetes, including cyclosporine, nicotinamide, BCG and the subcutaneous and intravenous administration of insulin. He is currently one of nine center directors for the Diabetes Prevention Trial (DPT-1). Development of strategies aimed at prevention of the eye and kidney complications of type I diabetes, based upon controlling HbA1c levels and blood pressure levels. His first longitudinal report of HbA1c levels in relation to diabetic eye and kidney complications was reported in JAMA in 1989. The development of new insulins and their use in children: he was the first to report the use of postprandial Humalog in toddlers and on the use of Humalog in the phone management of ketonuria. Ketoacidosis has been of interest for many years (Pediatrics in Review, 1990). A report is now in progress relating to the prevention of severe DKA and cerebral edema. Continuous glucose monitoring (CGM) in children has been a recent area of emphasis. The use of CGM to prevent severe hypoglycemia and to improve HbA1c levels is currently being studied
Clinical Location: Aurora - Barbara Davis Center for Childhood Diabetes - Specialty Clinic
Clinic Phone: 303-724-2323
Fax Phone: 303-724-6784
Research Interest for Referring Providers: Clinical trials of agents for the prevention of type I diabetes, including cyclosporine, nicotinamide, BCG and the subcutaneous and intravenous administration of insulin. He is currently one of nine center directors for the Diabetes Prevention Trial (DPT-1). Development of strategies aimed at prevention of the eye and kidney complications of type I diabetes, based upon controlling HbA1c levels and blood pressure levels. His first longitudinal report of HbA1c levels in relation to diabetic eye and kidney complications was reported in JAMA in 1989. The development of new insulins and their use in children: he was the first to report the use of postprandial Humalog in toddlers and on the use of Humalog in the phone management of ketonuria. Ketoacidosis has been of interest for many years (Pediatrics in Review, 1990). A report is now in progress relating to the prevention of severe DKA and cerebral edema. Continuous glucose monitoring (CGM) in children has been a recent area of emphasis. The use of CGM to prevent severe hypoglycemia and to improve HbA1c levels is currently being studied
Hospital Affiliation
Children's Hospital Colorado
Children's Hospital Colorado
Clinical Location: Aurora - Barbara Davis Center for Childhood Diabetes - Specialty Clinic
Clinic Phone: 303-724-2323
Fax Phone: 303-724-6784






